To read all of these articles and more, visit centerforbiosimilars.com.

Celltrion will cancel treasury shares worth 203.3 billion won ($140 million) to enhance shareholder value, the Korean drugmaker said on Friday.

South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma, a ...

As global markets face challenges from tariff uncertainties and inflation concerns, Asian tech stocks have shown resilience, with China's indices posting gains amid economic growth targets and ...

Celltrion launches Steqeyma autoimmune treatment in U.S. market Celltrion unveils its competitive approach for Steqeyma in ...

Steqeyma, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is ...

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...